<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/690BC3F7-F744-4681-8593-8FA07A3CF427"><gtr:id>690BC3F7-F744-4681-8593-8FA07A3CF427</gtr:id><gtr:firstName>Jeffrey</gtr:firstName><gtr:otherNames>Keith</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902269"><gtr:id>7C9579B2-9FBF-48E8-914C-045C8A5D03E0</gtr:id><gtr:title>Generation of suppressive donor T cells to specifically control alloresponses after allogeneic stem cell transplantation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902269</gtr:grantReference><gtr:abstractText>Allogeneic stem cell transplantation consists of the transfer of blood stem cells (or bone marrow) from a healthy donor to a patient. This procedure can cure patients with many diseases that would be otherwise incurable, including those with cancers of the blood such as leukaemia. However, a major problem that limits the success of allogeneic stem cell transplantation is graft-versus-host disease, which is the destruction of healthy patient tissues by donor immune cells contained within the transplant. Current techniques to prevent graft-versus-host disease are unsatisfactory as they suppress the recovery of all immune cells, resulting in increased infection and cancer relapse after transplant. We have recently identified a way of manipulating human donor cells before allogeneic transplantation that leads to the production of immune cells which can suppress graft-versus-host disease responses. The aim of this project is to develop ways in the laboratory to improve this technique to provide donor immune cells which could be used to prevent graft-versus-host disease without affecting the healthy recovery of the immune system after allogeneic transplantation. We hope that this might lead to a better way to prevent graft-versus-host disease after allogeneic transplantation, making this a safer and more effective treatment.</gtr:abstractText><gtr:technicalSummary>Allogeneic haematopoietic stem cell transplantation (AHSCT) can cure patients with many diseases for which no effective alternative therapy exists. A major challenge to AHSCT is graft-versus-host disease (GvHD), mediated by alloreactive donor T cells which recognize and damage healthy patient tissues. Current methods to prevent GvHD are unsatisfactory, delaying reconstitution of beneficial donor T cells and increasing infection and disease relapse. The development of strategies to selectively reduce alloreactive T cell responses could improve the outcome of AHSCT. One such strategy is alloanergization, the inactivation of alloreactive donor T cells by allostimulation with co-stimulatory blockade. Alloanergization preserves pathogen-specific T cell responses. In early clinical studies, transplantation of alloanergized HLA-mismatched donor T cells within bone marrow resulted in rapid immune reconstitution, few infections and low rates of GvHD. We have recently shown that the strategy of alloanergization results in the generation of regulatory T cells (Treg) which specifically suppress alloreactive donor T cell responses. We therefore hypothesise that alloanergized donor cells could be used for specific prophylaxis of GvHD after AHSCT. The development of alloanergization as a strategy to generate Treg which prevent GvHD without impairing graft-versus-leukaemia (GvL) effects after AHSCT is the objective of this project. The first aim is to potentiate the generation of allospecific Treg following alloanergization. We will use in vitro assays to determine the effects of epigenetic modulation of FOXP3 expression on the frequency, suppressive function and migratory capacity of Treg generated by alloanergization of human peripheral blood mononuclear cells (PBMC). To broaden the applicability of the approach, we will also modify the strategy for use with HLA-matched unrelated donors using established approaches to augment antigen-presentation. The second aim is to determine if alloanergized cells can prevent human T cells from causing GvHD in vivo. This will be achieved using adoptive transfer of human PBMC with and without alloanergized cells into immunodeficient NOD/SCID/IL2R-/- mice in a xenogeneic model of human T cell-mediated GvHD. Finally, a critical component for successful use of alloanergized human cells to prevent GvHD after AHSCT is the preservation of GvL effects. Our third aim is to enhance donor cell-mediated GvL effects after alloanergization by employing non-haematopoietic antigen-presenting cells to spare tissue-restricted minor histocompatibility antigen-directed T cell responses, and to augment alloreactive donor NK cell responses after alloanergization. This project could lead to development of effective clinical strategies to deliver antigen-specific cellular prophylaxis of GvHD which could improve the outcome of ASCT.</gtr:technicalSummary><gtr:fund><gtr:end>2015-05-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1450107</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>Expanding peripheral blood derived endothelial cells for use as tolerizing antigen-presenting cells</gtr:description><gtr:id>4F4780BD-5047-47C7-A838-CEACF61738DC</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>qWNkiS4xd2S-1</gtr:outcomeId><gtr:partnerContribution>helped my group with ex vivo cell culture approaches</gtr:partnerContribution><gtr:piContribution>developing assays to assess antigen-presenting cell capacity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Medical Oncology</gtr:department><gtr:description>Using humanized anti-B7 antibodies for costimulatory blockade to separate allospecific effector T cell and regulatory T cell responses</gtr:description><gtr:id>3760BF99-8980-424B-8FBF-F9B859CC54E1</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>LX5CTh8G1ZV-1</gtr:outcomeId><gtr:partnerContribution>source of reagents</gtr:partnerContribution><gtr:piContribution>collaborative experimental desigh and execution</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visis st Albans</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F1363B65-4DAE-4E95-93AF-745F411AC0DE</gtr:id><gtr:impact>pupils attanded a working in science workshop

school reported interest from several individuals after workshop</gtr:impact><gtr:outcomeId>BKFmmdVfcBo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grants</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Bloodwise</gtr:fundingOrg><gtr:id>A39F1AB4-7252-4D04-8A26-97DE673F5460</gtr:id><gtr:outcomeId>56dda3b57dd2b2.92004798</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>small project grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>365806AE-9BD5-40B5-A956-EC03687A1BFB</gtr:id><gtr:outcomeId>56dda458b52933.07237782</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>clinical research fellowship</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>53D8DB63-4F67-4B67-84CA-43E8C17B58D2</gtr:id><gtr:outcomeId>56dda416c4b4f0.20449432</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3787C111-50E0-41BD-BDEC-2577EE14C49C</gtr:id><gtr:title>Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1e668f5f9fc67de86d4b29954489578"><gtr:id>d1e668f5f9fc67de86d4b29954489578</gtr:id><gtr:otherNames>Barbon CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>AURULNxh9By</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AD56589-3DB2-4655-8090-3EE710537E44</gtr:id><gtr:title>TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7353abeccc8a83a0eb312f8a141d830e"><gtr:id>7353abeccc8a83a0eb312f8a141d830e</gtr:id><gtr:otherNames>Kotsiou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>585d68d5c63df5.70972997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>892183DD-006C-4E3C-9F11-F2EE2F2178A7</gtr:id><gtr:title>Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0de6d91345849fe21569f19d681a546"><gtr:id>f0de6d91345849fe21569f19d681a546</gtr:id><gtr:otherNames>Davies JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>mUoDHTfETHm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>324FED3D-8469-432D-BD8A-E51057BE8A60</gtr:id><gtr:title>Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0de6d91345849fe21569f19d681a546"><gtr:id>f0de6d91345849fe21569f19d681a546</gtr:id><gtr:otherNames>Davies JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_16544_24_23718277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7661F99-CE21-4184-9ED0-3D1AC974A943</gtr:id><gtr:title>New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7353abeccc8a83a0eb312f8a141d830e"><gtr:id>7353abeccc8a83a0eb312f8a141d830e</gtr:id><gtr:otherNames>Kotsiou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_16544_24_23121307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66936A3D-201F-42DC-A58E-E8DADFB42B8D</gtr:id><gtr:title>Blockade of chemotaxis in graft-versus-host disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0de6d91345849fe21569f19d681a546"><gtr:id>f0de6d91345849fe21569f19d681a546</gtr:id><gtr:otherNames>Davies JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_16544_24_23094739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>304F6EFF-F539-4031-885D-F9E1747C9753</gtr:id><gtr:title>T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2879ec3bcb8a21f67ff5fe649a117d2e"><gtr:id>2879ec3bcb8a21f67ff5fe649a117d2e</gtr:id><gtr:otherNames>Riches JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>k2jRQGUBRxH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD4DE6BB-8580-4C75-B5D0-607C442D1B7F</gtr:id><gtr:title>Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7353abeccc8a83a0eb312f8a141d830e"><gtr:id>7353abeccc8a83a0eb312f8a141d830e</gtr:id><gtr:otherNames>Kotsiou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>585d68d26d5d12.15180755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9930ACB-F156-45E4-9B17-7FE47E500536</gtr:id><gtr:title>T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1239c27ee29f17606da3ff1b02bd4d0a"><gtr:id>1239c27ee29f17606da3ff1b02bd4d0a</gtr:id><gtr:otherNames>Auer RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_16544_24_22449197</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902269</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>